300 related articles for article (PubMed ID: 19663760)
1. Discontinued drugs in 2008: oncology drugs.
Williams R
Expert Opin Investig Drugs; 2009 Nov; 18(11):1581-94. PubMed ID: 19663760
[TBL] [Abstract][Full Text] [Related]
2. Discontinued drugs in 2006: oncology drugs.
Williams R
Expert Opin Investig Drugs; 2008 Mar; 17(3):269-83. PubMed ID: 18321227
[TBL] [Abstract][Full Text] [Related]
3. Discontinued drugs 2011: pulmonary, allergy, gastrointestinal and arthritis.
Antoniu SA
Expert Opin Investig Drugs; 2012 Nov; 21(11):1607-18. PubMed ID: 22839355
[TBL] [Abstract][Full Text] [Related]
4. 27th Annual JPMorgan Healthcare Conference--BioCryst and Emergent Biosolutions.
Croasdell G; Gale S
IDrugs; 2009 Mar; 12(3):149-51. PubMed ID: 19333891
[No Abstract] [Full Text] [Related]
5. Phase 0 clinical trials in oncology: a paradigm shift for early drug development?
Takimoto CH
Cancer Chemother Pharmacol; 2009 Mar; 63(4):703-9. PubMed ID: 18615251
[TBL] [Abstract][Full Text] [Related]
6. Discontinued drugs in 2008: cardiovascular drugs.
Zhang XS; Xiang BR
Expert Opin Investig Drugs; 2009 Jul; 18(7):875-85. PubMed ID: 19548849
[TBL] [Abstract][Full Text] [Related]
7. [Drug development in paediatric oncology].
Benninger-Döring G; Boos J
Klin Padiatr; 2006; 218(3):152-6. PubMed ID: 16688671
[TBL] [Abstract][Full Text] [Related]
8. The role of the National Cancer Institute in drug development.
Doroshow J
Clin Adv Hematol Oncol; 2005 Apr; 3(4):257-8. PubMed ID: 16166997
[No Abstract] [Full Text] [Related]
9. Trends in risks associated with new drug development: success rates for investigational drugs.
DiMasi JA; Feldman L; Seckler A; Wilson A
Clin Pharmacol Ther; 2010 Mar; 87(3):272-7. PubMed ID: 20130567
[TBL] [Abstract][Full Text] [Related]
10. Clinical trial transparency: registries, databases raise questions, stir debate.
Benowitz S
J Natl Cancer Inst; 2005 Nov; 97(22):1640-1. PubMed ID: 16288115
[No Abstract] [Full Text] [Related]
11. BMS-247550 Bristol-Myers Squibb/GBF.
Lin N; Brakora K; Seiden M
Curr Opin Investig Drugs; 2003 Jun; 4(6):746-56. PubMed ID: 12901236
[TBL] [Abstract][Full Text] [Related]
12. Discontinued drugs in 2011: cardiovascular drugs.
Zhao HP; Jiang HM; Xiang BR
Expert Opin Investig Drugs; 2012 Oct; 21(10):1449-62. PubMed ID: 22827213
[TBL] [Abstract][Full Text] [Related]
13. Lapatinib ditosylate GlaxoSmithKline.
Kim TE; Murren JR
IDrugs; 2003 Sep; 6(9):886-93. PubMed ID: 12964069
[TBL] [Abstract][Full Text] [Related]
14. TLK-286.
Verschraegen CF; Smith HO; Lee FC; Cathcart C; Norenberg JP
IDrugs; 2004 Aug; 7(8):771-81. PubMed ID: 15334311
[TBL] [Abstract][Full Text] [Related]
15. BAY-43-9006 Bayer/Onyx.
Lee JT; McCubrey JA
Curr Opin Investig Drugs; 2003 Jun; 4(6):757-63. PubMed ID: 12901237
[TBL] [Abstract][Full Text] [Related]
16. ZD-6126 AstraZeneca.
Soltau J; Drevs J
IDrugs; 2004 Apr; 7(4):380-7. PubMed ID: 15057644
[TBL] [Abstract][Full Text] [Related]
17. Diflomotecan. Ipsen.
Osheroff N
IDrugs; 2004 Mar; 7(3):257-63. PubMed ID: 15011101
[No Abstract] [Full Text] [Related]
18. Learning from exceptional drug responders.
Mullard A
Nat Rev Drug Discov; 2014 Jun; 13(6):401-2. PubMed ID: 24875081
[No Abstract] [Full Text] [Related]
19. Economics of new oncology drug development.
DiMasi JA; Grabowski HG
J Clin Oncol; 2007 Jan; 25(2):209-16. PubMed ID: 17210942
[TBL] [Abstract][Full Text] [Related]
20. Discontinued drugs in 2010: cardiovascular drugs.
Zhao HP; Zhang XS; Xiang BR
Expert Opin Investig Drugs; 2011 Oct; 20(10):1311-25. PubMed ID: 21870899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
